Raludotatug Deruxtecan Gets FDA Breakthrough for Ovarian Cancer
September 15, 2025
First Breakthrough Therapy Designation for Daiichi Sankyo and Merck’s raludotatug deruxtecan based on phase 1 trial and REJOICE-Ovarian01 phase 2/3 trial Raludotatug deruxtecan (R-DXd) has